Global Recombinant DNA Technology Market to Reach USD 1338.54 billion by 2032., Aided by Growing R&D Activities

The market for recombinant DNA technology is being driven by rising research and development activities to cure or alleviate diseases such as cancer and other immunodeficiency ailments. Developments in genetically engineered human insulin to treat diabetes and the success rate of the treatment has triggered the innovation of several other drugs, which is also fuelling the market growth.

Furthermore, the application of recombinant DNA technology to produce genetically modified crops that are rich in quality is also providing further impetus to the market growth. The use of recombinant DNA technology in agricultural activities has led to cost-efficient production, thus, adding to the market growth. In addition to its rising adoption in downstream sectors, the technology have no negative impact on the environment or human health, further spurring the market growth of recombinant DNA technology.

In 2020, one of the leading companies in recombinant DNA technology, Sanofi (OTCMKTS: SNYNF) collaborated with GSK to develop an adjuvanted COVID-19 vaccine using innovative and advanced technologies. Sanofi used its S-protein COVID-19 antigen based on recombinant DNA technology. The technology has produced an exact match to the proteins found in the virus, and further proceedings will take place with the help of the baculovirus expression platform. Sanofi’s initiative to develop a vaccine against coronavirus is a major breakthrough for the company and is expected to propel the overall growth of the industry in the coming years. The development of recombinant-based COVID-19 vaccine by Sanofi is being supported by Biomedical Advanced Research and Development Authority (BARDA). Such government aid in the form of investments is expected to further aid the market growth of recombinant DNA technology over the forecast period.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Analysis by Product, Component, Application, End Use, and Region:

• On the basis of product, the market is divided into medical and non-medical. Medical products are further segmented into therapeutic agent, human protein, and vaccine, while non-medical products are divided into biotech crops, speciality chemicals, and others.

• Based on component, the market is divided into expression system and cloning vector. Expression system is further sub-divided into mammalian, bacteria, yeast, and baculovirus/insects.

• On the basis of application, the market is categorised into food and agriculture, health and disease, environment, and others. Health and disease are further categorised into human and animal.

• Based on end use, the market is divided into biotechnology and pharmaceutical companies, academic and government research institutions, and others.

• The regional markets for recombinant DNA technology are North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.

Key Findings of the Report:

• The market for recombinant DNA Technology is being driven by the growing research and development (R&D) programmes to treat life threatening diseases like cancer, diabetes, and other immune deficiency diseases.

• The recombinant DNA technology can be applied to produce transgenic animals, which provides tremendous opportunities to study gene regulation and disease, thereby adding to the market growth. 

• The rising use of recombinant DNA in the agricultural sector to produce genetically modified crops is further invigorating market growth.

• Research and Development (R&D) activities to produce genetically modified plants with the ability to withstand extreme environmental conditions in the coming years are anticipated to strengthen the market.

Key Offerings of the Report:

• The EMR report gives an overview of the global market for recombinant DNA technology for the periods (2018-2023) and (2024-2032).

• The report also offers historical (2018-2023) and forecast (2024-2032) markets for products, components, applications, end use, and major regions for recombinant DNA technology.

• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with an assessment of the SWOT and Porter’s Five Forces model.

The major players in the global recombinant DNA technology market are Sanofi, Amgen Inc., Genentech Inc., GenScript, and Profacgen, among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

About Us

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over a 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us

Expert Market Research
Website: www.expertmarketresearch.com
Email: [email protected]
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790